Compare Consolidated Edison, Inc. (ED) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Consolidated Edison, Inc. vs Inovio Pharmaceuticals Inc — how do they compare? Consolidated Edison, Inc. trades at $111.99 (market cap $40.65B), while Inovio Pharmaceuticals Inc trades at $1.16 (market cap $96.26M). The key difference: Consolidated Edison, Inc. is far larger — about 422.3× Inovio Pharmaceuticals Inc's market cap, and Consolidated Edison, Inc. pays a 3.15% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| ED | INO | |
|---|---|---|
Market Cap | $40.65B | $96.26M |
Sector | Utilities | Health |
52-Week High | $115.46 | $2.87 |
52-Week Low | $95.37 | $1.05 |
Enterprise Value | $67.68B | $67.27M |
Dividend Yield | 3.15% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Con Edison (ED) trades at $111.94, showing modest daily gains. The stock exhibits a bullish technical trend with strong moving average signals, while recent earnings have been mixed with a Q1 2026 miss. Revenue growth is steady, supported by a 12.52% net income margin and a reasonable P/E of 18.6. Recent news highlights grid upgrades and electric fleet expansions, aligning with rising power demand trends.
ED offers stable income with a solid dividend history but faces risks from high debt levels and capital expenditure demands. Analyst consensus is cautious, with a hold-heavy rating and a price target below the current price, suggesting limited near-term upside amid macroeconomic and regulatory pressures.
INO trades at $1.16 with no recent price movement, reflecting its speculative biotech profile. The company shows consistent quarterly earnings beats but operates with minimal revenue ($65K in 2025) and significant losses (-$85M net income). Technical indicators are bearish overall, though some oscillators suggest potential oversold conditions. Recent news highlights the critical FDA decision for INO-3107 in October 2026 as the primary near-term catalyst.
The investment case hinges entirely on regulatory approval of INO-3107, with analysts maintaining a cautiously optimistic stance (53% buy ratings). However, substantial financial risks persist including negative cash flow, high burn rate, and shareholder litigation. Successful FDA approval could drive significant upside, while rejection would likely exacerbate financial pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Consolidated Edison, Inc.
Con Ed is a holding company for Consolidated Edison of New York, or CECONY, and Orange & Rockland, or O&R. These utilities provide steam, natural gas, and electricity to customers in southeastern New York—including New York City—and small parts of New Jersey. The two utilities will generate nearly all of Con Ed's earnings once it closes the sale of its clean energy business to RWE. Con Ed's clean energy business owns the second-largest portfolio of utility-scale solar projects in the U.S. Following the sale, Con Ed's only non-utility earnings will come from investments in gas and electric transmission.
Read more on ED →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
